Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Elizabeth A. Poplin"'
Publikováno v:
Journal of Clinical Oncology. 19:3801-3807
PURPOSE: To review and assign attribution for the causes of early deaths on two National Cancer Institute-sponsored cooperative group studies involving irinotecan and bolus fluorouracil (5-FU) and leucovorin (IFL). PATIENTS AND METHODS: The inpatient
Autor:
Elizabeth A. Poplin, Manuel Valdivieso, Laura F. Hutchins, Timothy J. Panella, John S. Macdonald, Joth Jacobson, Arnold Herskovic
Publikováno v:
Cancer. 78:1851-1856
BACKGROUND Continuous infusion 5-fluorouracil (CI5-FU) has been utilized concurrently with radiotherapy to improve tumor control. In this pilot trial, cisplatin, CI5FU, and radiotherapy were utilized for the treatment of locoregional esophageal carci
Autor:
Laura E. Gaspar, Vainutis K. Vaitkevicius, Elizabeth A. Poplin, Micheal J. Kraut, Glenn Cummings, Joseph L. Kinzie, B D O Paul Lattin, Zwi Steiger, Arnold Herskovic, Parvinderjit S. Khanuja
Publikováno v:
Cancer. 74:1217-1224
Background. Chemoradiotherapy has demonstrated efficacy in esophageal cancer but rarely is curative. To improve local control and decrease metastases, a 7-month regimen was used with standard-dose radiotherapy (RT), cisplatin (DDP), and continuous in
Autor:
Caio M, Rocha-Lima, Soley, Bayraktar, Jessica, Macintyre, Luis, Raez, Aurea M, Flores, Annapoorna, Ferrell, Eric H, Rubin, Elizabeth A, Poplin, Antoinette R, Tan, Antonio, Lucarelli, Naseem, Zojwalla
Publikováno v:
Cancer. 118(17)
E7974, a synthetic analog of hemiasterlin, interacts with the tubulin molecule and overcomes resistance to other antitubulin drugs (taxanes and vinca alkaloids).In a phase 1 study, E7974 was given intravenously over a 2- to 5-minute infusion on day 1
Autor:
Rebecca A, Moss, Dirk, Moore, Mary F, Mulcahy, Kenneth, Nahum, Biren, Saraiya, Simantini, Eddy, Martin, Kleber, Elizabeth A, Poplin
Publikováno v:
Gastrointestinal cancer research : GCR. 5(3)
The pancreatic tumor microenvironment is rich in receptors for platelet-derived growth factor (PDGFRs). Imatinib mesylate (IM) inhibits PDGFRs and decreases tumor interstitial fluid pressure, potentially improving drug access. These data and promisin
Autor:
Scott Wadler, N. J. Meropol, Eric Van Cutsem, Elizabeth A. Poplin, Mace L. Rothenberg, Harry Bleiberg, Angelo Di Leo
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 20(4)